OasisLMS

Upon completion of this program, participants will be able to:

1. Implement effective strategies to address stigma and bias in obesity management.
2. Accurately address common misconceptions about anti-obesity medications.
3. Develop patient-centered approaches to manage concerns and improve adherence to obesity treatments.

This educational program is designed for HCPs, including primary care physicians and advanced practice professionals, nurse practitioners, physician assistants, as well as endocrinologists who care for patients with obesity.

In the last ten years, the Federal Drug Administration (FDA) has approved multiple anti-obesity medications (AOMs) for use in the US. These new FDA-approved AOMs have sparked a surge in demand and have been met with a wave of news articles, opinion pieces, backlash, and criticism on social media, challenging the safety, effectiveness, and affordability of these treatments. Heathcare providers (HCPs) and patients are exposed to false information, misunderstandings, and prejudiced views about obesity AOMs on social media and other platforms. This exposure can distort their comprehension and perception of obesity, possibly resulting in delayed or unsuitable treatment approaches, stigmatization, and reduced quality of life, highlighting the need for clear, compassionate, and scientifically grounded communication in healthcare. Given the potential for misinformation to lead to delayed or inappropriate treatment and reduced patient quality of life, there is a pressing need for comprehensive, evidence-based education programs that will improve patient outcomes and foster a more informed and empathetic approach to obesity management.

Physicians
The American College of Endocrinology (ACE) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The American College of Endocrinology (ACE) designates this enduring activity for a maximum of 4.0 AMA PRA Category 1 Credits^TM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 4.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Only those who receive a passing score will be eligible for MOC credit.

Please allow two weeks for MOC points to appear in your account on the ABIM website. Participation information will be shared.

Nurses
American College of Endocrinology DBA American Association of Clinical Endocrinology (AACE) is approved by the California Board of Registered Nursing, Provider Number 17762, is eligible for up to 4.0 contact hours.

The American Association of Clinical Endocrinologists (AACE) remains strongly committed to providing the best available evidence-based clinical information to participants of this educational activity and requires an open disclosure of any potential conflict of interest identified by our faculty members. It is not the intent of AACE to eliminate all situations of potential conflicts of interest, but rather to enable those who are working with AACE to recognize situations that may be subject to question by others. All disclosed conflicts of interest are reviewed by the Continuing Medical Education (CME) Subcommittee to ensure that such situations are properly evaluated and, if necessary, resolved. AACE educational standards pertaining to conflicts of interest are intended to maintain the professional autonomy of the clinical experts inherent in promoting a balanced presentation of science. Through our review process, all AACE accredited activities are ensured of independent, objective, scientifically balanced presentations of information. Disclosure of any or no relationships will be made available for all educational activities.

All of the relevant financial relationships listed for these individuals have been mitigated. All other planners for this educational activity have no relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Planner Disclosures

Jaime Almandoz, MD, MBA, FTOS

• Consultant – Novo Nordisk, Eli Lilly, Boehringer Ingelheim, Nestle, AbbVie, Wave Life Sciences

Monisha Chadha, MD, FACE, CDCES

• No relationships to disclose

Jennifer Clements, PharmD

• Speakers’ Bureau - Novo Nordisk, Eli Lilly

Maria A. Mogollon, APRN

• Speakers’ Bureau - Novo Nordisk, Eli Lilly

All of the relevant financial relationships listed for these individuals have been mitigated. 
Faculty Disclosures

Jaime Almandoz, MD, MBA, FTOS

• Consultant – Novo Nordisk, Eli Lilly, Boehringer Ingelheim, Nestle, AbbVie, Wave Life Sciences

Monisha Chadha, MD, FACE, CDCES

• No relationships to disclose

Jennifer Clements, PharmD

• Speakers’ Bureau - Novo Nordisk, Eli Lilly

Maria A. Mogollon, APRN

• Speakers’ Bureau - Novo Nordisk, Eli Lilly

All of the relevant financial relationships listed for these individuals have been mitigated.